Ignite Creation Date:
2024-05-06 @ 5:45 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05411380
Status:
RECRUITING
Last Update Posted:
2022-11-04
First Post:
2022-06-05
Brief Title:
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive HER2-negative Breast Cancer After CDK46 Inhibitor
Sponsor:
wang shusen
Organization:
Sun Yat-sen University
Study Overview
Official Title:
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive HER2-negative Breast Cancer After CDK46 Inhibitora Prospective Single-arm Phase II Clinical Trial
Status:
RECRUITING
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is designed to explore the clinical benefit following treatment with tucidinosta in combination with metronomic capecitabine and endocrine therapy in patients with hormone receptor-positive Her2-negative advanced breast cancer who have received CDK46 Inhibitor treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None